Principles of nanoparticle design for overcoming biological barriers to drug delivery
By Elvin Blanco, Haifa Shen, Mauro Ferrari. Nature Biotechnology, 2015
6,044 citations recorded by the source corpus.
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Subfields: Biomaterials, Materials Chemistry, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/c22a994a0816e07d0f42d63f3f17b983f3af0e1e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Materials Chemistry
In Molecular Biology
Citations in the corpus
- DLS and zeta potential - What they are and what they are not? (2016, background): “, macromolecules [16], peptides [17]) and release at target sites (e.”
- The Smart Drug Delivery System and Its Clinical Potential (2016, background): “Most of nanoplatforms will not succeed in clinics if the biological barriers faced by the nanoparticles are not conquered [184].”
- Exosomes: key players in cancer and potential therapeutic strategy (2020, background): “Compared with liposome nanomaterials, metal nanomaterials, and polymer nanomaterials, exosomes as carriers can overcome the shortcomings of poor bioavailability and reduce non-targeted cytotoxicity and immunogenicity.(144,145) And exosomes contain transmembrane and membrane anchoring proteins, which”
- Progress in tumor-associated macrophage (TAM)-targeted therapeutics (2017, neutral): “While the natural tendency of M2 macrophages to more readily internalize nanoparticles could be beneficial for designing TAM-targeted therapy, the resident macrophages’ penchant for internalizing nanoparticles is still an important challenge in developing TAM-targeted therapies [185][186][181][187].”
- Cancer nanomedicine: a review of recent success in drug delivery (2017, background): “This phenomenon, known as the enhanced permeability and retention (EPR) effect, has been utilized for passive targeting of nanoparticles to tumor tissue, but deeper penetration into the tumor is frequently restricted due to heterogeneity of the tumor microenvironment [46].”